#integrase inhibitor

People who saw substantial CD4 T-cell gains during the first two years after diagnosis had better outcomes.

A high-quality trial should improve access to dolutegravir for children worldwide.

The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.

Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.

People who switched to such a regimen gained up to 10 pounds in nine months.

People who used long-acting Cabenuva preferred the injections over their previous daily oral regimen.

Taking meds for four days followed by three days off maintained viral suppression for two years.

However, all integrase inhibitors were associated with similar weight gain.

Switching to an integrase inhibitors is not tied to gain in bad fat, according to recent study.

Resistance to four HIV drug classes is tied to high risk of disease and death.

The antiretroviral drug class includes bictegravir, dolutegravir, elvitegravir and raltegravir.

A study looked at the fat composition of people who switched their antiretrovirals to include an integrase inhibitor.

This may reflect loss of the weight-suppressing effect of the older version of the drug.

Aging with HIV won’t slow down Robert Gillum.